Drug Courts pp 215-233 | Cite as

Drug Testing Methods

  • Karl Auerbach


The challenge in drug testing is to have a reliable, reproducible, and economical test that can be used to make critical decisions about peoples’ lives. The choice of which material to test is often a matter of which specimen is accessible and how people feel about how the sample is obtained. Testing methods depend on whether laboratory equipment is available and how well the methodology holds up to legal challenge. A concern expressed by some is that “any test with less than 100% accuracy is likely to produce a high percentage of false positives” (1). To date, there is no evidence that this is a valid concern with the testing procedures currently in place.


Drug Test Chronic Pain Patient Drug Court Hair Analysis Adolescent Substance Abuse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Grinspoon L, Bakalar JB. The war on drugs: a peace proposal. N Engl J Med 1994;330(5):357–360.PubMedCrossRefGoogle Scholar
  2. 2.
    National Institute on Drug Abuse. Urine Testing for Drugs of Abuse. NIDA Research Monograph Series 73. Washington, DC: National Institute on Drug Abuse; 1986.Google Scholar
  3. 3.
    Smith D. Medical Review Officer Course. Evanston, IL: American College of Occupational and Environmental Medicine; 2000.Google Scholar
  4. 4.
    Barnaby B, Drummond C, McCloud A, Burns T, Omu N. Substance misuse in psychiatric inpatients: comparison of a screening questionnaire survey with case notes. BMJ 2004;184:439–445.Google Scholar
  5. 5.
    Katz NP, Sherburne S, Beach M, Rose RJ, Vielguth J, Bradley J, Fanciullo GJ. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg 2003;97:1097–1102.PubMedCrossRefGoogle Scholar
  6. 6.
    Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Validity of self-reported drug use in chronic pain patients. Clin J Pain 1999;15(3):184–191.PubMedCrossRefGoogle Scholar
  7. 7.
    Ehrman RN, Robbins SJ, Cornish JW. Comparing self-reported cocaine use with repeated urine tests in outpatient cocaine abusers. Exp Clin Psychopharmacol 1997;5(2):150–156.PubMedCrossRefGoogle Scholar
  8. 8.
    Weiss RD, Najavits LM, Greenfield SF, Soto JA, Shaw SR, Wyner D. Validity of substance use self-reports in dually diagnosed outpatients. Am J Psychiatry 1998;155(1):127–128.PubMedGoogle Scholar
  9. 9.
    Calhoun PS, Bosworth HB, Hertzberg MA, Sampson WS, Feldman ME, Kirby AC, Wampler TP, Tate-Williams F, Moore SD, Beckman JC. Drug use and validity of substance use self-reports in veterans seeking help for posttraumatic stress disorder. J Consult Clin Psychol 2000;68(5):923–927.PubMedCrossRefGoogle Scholar
  10. 10.
    Mason D, Birmingham L, Grubin D. Substance use in remand prisoners: a consecutive case study. BMJ 1997;315(7099):18–23.PubMedGoogle Scholar
  11. 11.
    Lundy A, Gottheil E, McLellan AT, Weinstein SP, Sterling RC, Serota RD. Underreporting of cocaine use at post-treatment follow-up and the measurement of treatment effectiveness. J Nerv Ment Dis 1997;185(7): 459–462.PubMedCrossRefGoogle Scholar
  12. 12.
    Normand J, Salyards SD, Mahoney JJ. An evaluation of preemployment drug testing. J Appl Psychol 1990; 75(6):629–639.PubMedCrossRefGoogle Scholar
  13. 13.
    Kaye DL. Office recognition and management of adolescent substance abuse. Curr Opin Pediatr 2004; 16(5):532–541.PubMedCrossRefGoogle Scholar
  14. 14.
    Weinberg NZ, Rahdert E, Colliver JD, Glantz MD. Adolescent substance abuse: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1998;37(3):252–261.PubMedCrossRefGoogle Scholar
  15. 15.
    Fretthold D. Drug-testing methods and reliability. J Psychoactive Drugs 1990; 22(4):419–428.PubMedGoogle Scholar
  16. 16.
    Kilvert P, Bryant R. Drug testing has been used in schools for several years. BMJ 1996;312(7047): 1671.PubMedGoogle Scholar
  17. 17.
    Kazlauskas R, Howe C, Trout G. Strategies for rhEPO detection in sport. Clin J Sport Med 2002; 12(4):229–235.PubMedCrossRefGoogle Scholar
  18. 18.
    Annas GJ. Testing poor pregnant women for cocaine: physicians as police investigators. N Engl J Med 2001;344(22):1729–1732.PubMedCrossRefGoogle Scholar
  19. 19.
    Fraser A, Zamecnik J. Substance abuse monitoring by the Correctional Service of Canada. Ther Drug Monit 2003;25:723–727.PubMedCrossRefGoogle Scholar
  20. 20.
    Osterlo JD, Becker CE. Chemical dependency and drug testing in the workplace. West J Med 1990;152: 506–513.Google Scholar
  21. 21.
    Cone EJ. New Developments in Biological Measures of Drug Prevalence. NIDA Research Monograph Series 167. Washington, DC: National Institute on Drug Abuse; 1997:108–129.Google Scholar
  22. 22.
    Lessenger JE. Drug programs and testing. In Lessenger JE, ed. Agricultural Medicine: A Practical Guide. New York: Springer; 2006:98–112.CrossRefGoogle Scholar
  23. 23.
    Josefson D. Arkansas bans selling of clean urine to beat drug testing. BMJ 2003; 326(7384):300.PubMedCrossRefGoogle Scholar
  24. 24.
    Drury DL, Masci V, Jacobson JW, McNutt RA. Urine drug screening: can counterfeit urine samples pass inspection. J Occup Environ Med 1999;41(8): 622–624.PubMedCrossRefGoogle Scholar
  25. 25.
    Kapur B, Hershkop S, Koren G, Gaughan V. Urine fingerprinting: detection of sample tampering in an opiate dependency program. Ther Drug Monit 1999; 21(2):243–250.PubMedCrossRefGoogle Scholar
  26. 26.
    Fraser AD, Zamecnik J. Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators. Ther Drug Monit 2003;25(6):723–727.PubMedCrossRefGoogle Scholar
  27. 27.
    U.S. Department of Transportation. Procedure for Transportation Workplace Drug and Alcohol Testing Programs. Fed Reg 2004;69(216):64865–64868.Google Scholar
  28. 28.
    Barbanel C, Winkelman J, Fischer G, King A. Confirmation of the Department of Transportation criteria for a substituted urine specimen. J Occup Environ Med 2002;44(5):407–409.PubMedCrossRefGoogle Scholar
  29. 29.
    Ostrea E. Understanding drug testing in the neonate and the role of meconium analysis. J Perinat Neonat Nurs 2001;14(4):61–82.Google Scholar
  30. 30.
    Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit 2004; 26(2):200–205.PubMedCrossRefGoogle Scholar
  31. 31.
    Moeller MR. Hair analysis as evidence in forensic cases. Ther Drug Monit 1996;18(4):444–449.PubMedCrossRefGoogle Scholar
  32. 32.
    Kintz P. Drug testing in addicts: a comparison between urine, sweat, and hair. Ther Drug Monit 1996; 18(4):450–455.PubMedCrossRefGoogle Scholar
  33. 33.
    Kintz P, Villain M, Ludes B. Testing for the undetectable in drug-facilitated sexual assault using hair analyzed by tandem mass spectrometry as evidence. Ther Drug Monit 2004;26(2):211–214.PubMedCrossRefGoogle Scholar
  34. 34.
    Miller M, Donnelly B, Martz R. The Forensic Application of Testing Hair for Drugs of Abuse. NIDA Research Monograph Series 167. Washington, DC: National Institute on Drug Abuse; 1997:146–159.Google Scholar
  35. 35.
    Kintz P, Samyn N. Use of alternative specimens: drugs of abuse in saliva and doping agents in hair. Ther Drug Monit 2002;24(2):239–246.PubMedCrossRefGoogle Scholar
  36. 36.
    Hoffman BH. Analysis of race effects on drug-test results. J Occup Environ Med 1999;41(7): 612–614.PubMedCrossRefGoogle Scholar
  37. 37.
    Cone EJ. Mechanisms of drug incorporation into hair. Ther Drug Monit 1996;18(4):438–443.PubMedCrossRefGoogle Scholar
  38. 38.
    Vinner E, Vignau J, Thibault D, Codaccioni X, Brassart C, Humbert L, Lhermitte M. Neonatal hair analysis contribution to establishing a gestational drug exposure profile and predicting a withdrawal syndrome. Ther Drug Monit 2003;25(4):421–432.PubMedCrossRefGoogle Scholar
  39. 39.
    Ostrea EM Jr, Knapp DK, Tannenbaum L, Ostrea AR, Romero Al, Salari V, Ager J. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, meconium analysis. J Pediatr 2001;138(3): 344–348.PubMedCrossRefGoogle Scholar
  40. 40.
    Toennes S, Steinmeyer S, Maurer H, Moeller MR, Kauert GF. Screening for drugs of abuse in oral fl uid— correlation of analysis results with serum in forensic cases. J Anal Toxicol 2005;29:22–27.PubMedGoogle Scholar
  41. 41.
    Palmeri A, Pichini S, Pacifici R, Zuccaro P, Lopez A. Drugs in nails. Clin Pharmacokinet 2000; 38(2):95–110.PubMedCrossRefGoogle Scholar
  42. 42.
    Forrest A. Guidelines are needed if drug testing those arrested by the police becomes compulsory. BMJ 2000;320(7226):56.PubMedCrossRefGoogle Scholar
  43. 43.
    Gore SM, Bird AG. Mandatory drug tests in prison. BMJ. 1995;310(6979):595.PubMedGoogle Scholar
  44. 44.
    Gentilello LM, Samuels PN, Henningfield JE, Santora PB. Alcohol screening and intervention in trauma centers: confi dentiality concerns and legal considerations. J Trauma Inj Infect Crit Care 2005;59:1250–1255.CrossRefGoogle Scholar
  45. 45.
    U.S. Nuclear Regulatory Commission. Fitness for duty programs. Fed Reg 1989;54:24494.Google Scholar
  46. 46.
    Swotinsky RB, Smith DR. The Medical Review Officer’s Manual: MROCC’s Guide to Drug Testing, 3rd ed. Beverly Farms, MA: OEM Press; 2006.Google Scholar
  47. 47.
    Milkelsen S, Ash KO. Adulterants causing false negatives in illicit drug testing. Clin Chem 1988; 34(11):2333–2336.Google Scholar
  48. 48.
    Cooper G, Wilson L, Reid C, Baldwin D, Hand C, Spiehler V. Validation of the Cozart® microplate EIA for analysis of opiates in oral fluid. Forensic Sci Int 2005;154(2–3):240–246.PubMedCrossRefGoogle Scholar
  49. 49.
    Cirimele V, Kintz P, Lohner S, Ludes B. Enzyme immunoassay validation for the detection of buprenorphine in urine. J Anal Toxicol 2003;27:103–105.PubMedGoogle Scholar
  50. 50.
    Cirimele V, Etienne S, Villain M, Ludes B, Kintz P. Evaluation of the One-step™ ELISA kit for the detection of buprenorphine in urine, blood and hair specimens. Forensic Sci Int 2004;143(2–3): 153–156.PubMedCrossRefGoogle Scholar
  51. 51.
    Dasgupta A, Chught O, Hannah C, Davis B, Wells A. Comparison of spot tests with AdultaCheck 6 and Intect 7 urine test strips for detecting the presence of adulterants in urine specimens. Clin Chim Acta 2004; 348(1–2):19–25.PubMedCrossRefGoogle Scholar
  52. 52.
    Peace M, Tarnai L. Performance evaluation of three on-site adulterant detection devices for urine specimens. J Anal Toxicol 2002;26(7):464–470.PubMedGoogle Scholar
  53. 53.
    Dasgupta A, Wahed A, Wells A. Rapid spot tests for detecting the presence of adulterants in urine specimens submitted for drug testing. Am J Clin Pathol 2002;17:325–329.Google Scholar
  54. 54.
    Wu A, Bristol B, Sexton K, Cassella-McLan G, Holtman V, Hill D. Adulteration of urine by “Urine Luck.” Clin Chem 1999;45(7):1051–1057.PubMedGoogle Scholar
  55. 55.
    Paul BD, Jacobs A. Spectrophotometric detection of iodide and chromic (III) in urine after oxidation to iodine and chromate (VI). J Anal Toxicol 2005;29:658–663.PubMedGoogle Scholar
  56. 56.
    Paul BD, Jacobs A. Effects of oxidizing adulterants of detection 11-nor-delta9-THC-9-carboxylic acid in urine. J Anal Toxicol 2002;26(7):460–463.PubMedGoogle Scholar
  57. 57.
    Wong R, Tran M, Tung J. Oral fluid drug tests: effects of adulterants and food-stuffs. Forensic Sci Int 2005;150(2–3):175–180.PubMedCrossRefGoogle Scholar
  58. 58.
    Pulini M. False-positive benzodiazepine urine test due to oxaprozin. JAMA 1995;273(24):1905.PubMedCrossRefGoogle Scholar
  59. 59.
    Lindsey RB, Horowitz G, Jacoby H, Eliopoulos G. Quinolones and false-positive urine screening for opiates by immunoassay technology. JAMA 2001;26:3115–3119.Google Scholar
  60. 60.
    Valentine JL, Komoroski EM. Use of a visual panel detection method for drugs of abuse: Clinical and laboratory experience with children and adolescents. J Pediatr 1995;126(1):135–140.PubMedCrossRefGoogle Scholar
  61. 61.
    Peat MA. Analytical and technical aspects of testing for drug abuse; confirmatory procedures. Clin Chem 1988;34(3):471–473.PubMedGoogle Scholar
  62. 62.
    Nordgren HK, Beck O. Multicomponent screening for drugs of abuse. Ther Drug Monit 2004;26(1): 90–97.PubMedCrossRefGoogle Scholar
  63. 63.
    Taylor PJ, Forrest KK, Landsberg PG, Mitchell C, Pillans PI. The measurement of nicotine in human plasma by high performance liquid chromatography-electrospray-tandem mass spectrometry. Ther Drug Monit 2004;26(5): 563–568.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Karl Auerbach
    • 1
  1. 1.Department of Environmental Medicine (Occupational Medicine Division)University of RochesterRochesterUSA

Personalised recommendations